The solar power provider slashed its initial public offering from $150m to $55.2m after suspending it citing market conditions.

The biosimilar developer, backed by Eli Lilly, Daaichi Sankyo and Medpace, will use the proceeds from its initial public offering to advance three of its product candidates.

Shareholders Novo and Johnson & Johnson invested a total of $4.6m as the neurostimulation device maker went public in a flotation that could rise to almost $145m.

The MedImmune-backed glaucoma treatment developer aims to raise up to $86.3m from its initial public offering, as well as an additional $46m in convertible debt.

Napo Pharmaceuticals-backed pet medicine developer Jaguar Animal Health is set to raise $40.4m if it floats at the middle of its range.

The Johnson & Johnson-backed small protein-based treatment developer raised $102m two weeks after initially suspending the initial public offering due to market conditions.

Novo is set to invest up to $16m as the Johnson & Johnson, Covidien and Mayo Clinic-backed company goes public.

The corporate-backed company, which is developing treatments for peanut and milk allergies, secured $92.6m after raising approximately $50m in venture funding.

The China-based solar power producer will float in the US after setting a range if between $10 and $12m for the offering.

The Amgen and Celgene-backed pharmaceutical company raised the cash after pulling in $72m in venture funding over two years.